Excess adiposity causally elevates serum uric acid (SUA) through at least four converging mechanisms: insulin resistance impairing renal urate excretion, visceral fat promoting urate synthesis, dietary patterns, and metabolic dysregulation. Mendelian randomization data tip the causal arrow firmly toward adiposity causing hyperuricemia rather than the reverse. Bariatric surgery delivers the largest sustained SUA reductions and meaningfully cuts gout incidence long-term, despite a transient postoperative SUA spike — likely from rapid tissue catabolism. GLP-1 receptor agonists and tirzepatide also reduce SUA, an effect attributed primarily to weight loss rather than direct urate-pathway action.
Gout has historically been managed through urate-lowering drugs like allopurinol and dietary purine restriction — neither of which addresses the adiposity root cause. Reframing obesity as a modifiable upstream driver, not merely a comorbidity, is clinically significant for the estimated 40 million gout sufferers worldwide whose disease burden tracks closely with BMI. The GLP-1 angle is particularly timely: if SUA reductions from semaglutide or tirzepatide prove robust in dedicated trials, these agents could simultaneously address gout, cardiovascular risk, and metabolic syndrome — conditions that cluster heavily in the same patients. Critical limitations apply: this is a narrative review, not a meta-analysis, making effect-size pooling impossible. Causality for pharmacological interventions on gout-specific endpoints remains largely inferred. Still, the mechanistic coherence and Mendelian randomization support make this more than incremental — it represents a meaningful paradigm shift toward metabolic root-cause management of gout.
